Ultragenyx Pharmaceutical (RARE) to Release Earnings on Tuesday

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of ($1.45) per share for the quarter. Ultragenyx Pharmaceutical has set its FY 2024 guidance at EPS.Parties interested in participating in the company's conference call can do so using this link.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The company had revenue of $147.03 million during the quarter, compared to analyst estimates of $123.20 million. During the same quarter last year, the firm posted ($2.25) EPS. The business's revenue for the quarter was up 35.7% on a year-over-year basis. On average, analysts expect Ultragenyx Pharmaceutical to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Ultragenyx Pharmaceutical Trading Down 1.8 %

Shares of RARE traded down $0.96 during midday trading on Wednesday, hitting $51.84. The stock had a trading volume of 721,991 shares, compared to its average volume of 766,066. Ultragenyx Pharmaceutical has a fifty-two week low of $32.83 and a fifty-two week high of $60.37. The business has a 50-day simple moving average of $56.02 and a two-hundred day simple moving average of $47.79. The firm has a market cap of $4.31 billion, a P/E ratio of -6.46 and a beta of 0.57.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total transaction of $1,003,400.00. Following the sale, the chief executive officer now owns 2,243,985 shares in the company, valued at $112,580,727.45. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at $4,869,800.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of the company's stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total transaction of $1,003,400.00. Following the transaction, the chief executive officer now owns 2,243,985 shares in the company, valued at approximately $112,580,727.45. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,556 shares of company stock worth $2,519,367 over the last 90 days. Insiders own 5.80% of the company's stock.

Analyst Upgrades and Downgrades

RARE has been the subject of several recent analyst reports. TD Cowen raised their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Cantor Fitzgerald reissued an "overweight" rating and issued a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, October 22nd. The Goldman Sachs Group increased their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Barclays cut their price objective on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an "overweight" rating on the stock in a research report on Monday, August 5th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus target price of $85.08.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.